Rapid and selective UV spectrophotometric and RP-HPLC methods for dissolution studies of oxybutynin immediate-release and controlled-release formulations

Journal of Pharmaceutical and Biomedical Analysis

Volumn 36, Issue 3, 2004, Pages 669-674

  Varma, Manthena V S ^a   Kaushal, Aditya M ^a   Garg, Sanjay ^a,b  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Dissolution study; Oxybutynin hydrochloride; RP HPLC; UV spectroscopy

Indexed keywords

ACETONITRILE; CHLOROFORM; CYSTRAN 5; METHANOL; OXYBUTYNIN; OXYMAT; OXYOS; PICRIC ACID; WATER;

ABSORPTION; ACCURACY; ANALYTICAL EQUIPMENT; ARTICLE; COMPLEX FORMATION; CONTROLLED RELEASE FORMULATION; DRUG SOLUBILITY; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TABLET FORMULATION; ULTRAVIOLET SPECTROPHOTOMETRY;

CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DELAYED-ACTION PREPARATIONS; MANDELIC ACIDS; SOLUBILITY; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 7444261887     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2004.07.044     Document Type: Article

References (20)

1. C.M. Fredericks, G.F. Anderson, and D.J. Kreulen Invest. Urol. 12 1975 317 319
2. A.C. Diokno, and J. Lapides J. Urol. 108 1972 307 309
3. T. Lackner, and C. Maloney Consul. Pharm. 14 1999 7 10
4. E. Miyamoto, S. Kawashima, Y. Murata, Y. Yamada, Y. Demizu, H. Kontani, and T. Sakai Analyst 119 1994 1489 1492
5. K. Waldeck, B. Larsson, and K.E. Andersson J. Urol. 157 1997 1093 1097
6. E. Lukkari, A. Juhakoski, K. Aranko, and P.J. Neuvonen Eur. J. Clin. Pharmacol. 52 1997 403 406
7. K.M. Hughes, J.C. Lang, R. Lazare, D. Gordon, S.L. Stanton, J. Malone-Lee, and M. Geraint Xenobiotica 22 1992 859 869
8. E. Lukkari, K. Aranko, A. Juhakoski, T. Hakonen, and P.J. Neuvonen Pharmacol. Toxicol. 81 1997 31 34
9. R.H. Zobrist, B. Schmind, A. Feick, D. Quan, and S.W. Sanders Pharm. Res. 18 2001 1029 1034
10. P.B. Geraghty, D. Attwood, J.H. Collett, and Y. Dandiker Pharm. Res. 13 1991 1265 1271
11. T. Ishikawa, Y. Watanabe, U. Naoki, and M. Matsumoto Chem. Pharm. Bull. 47 1999 1451 1454
12. USP24-NF19, Oxybutynin chloride, United States Pharmacopoeial Convention, Inc., Rockville, MD, 2000, pp. 1232-1233.
13. J.A. Schutter, and P. de Moerloose J. Chromatogr. 450 1988 337 342
14. R.K. Verma, and S. Garg J. Pharm. Biomed. Anal. 30 2002 583 591
15. Guidance for Industry, Q2B Validation of Analytical procedures: methodologies, US Department of Health and Human Services US FDA, Center for Drug Evaluation and Research, Rockville, MD, USA, November 1996.
16. R. Panchagnula, T. Bansal, M.V.S. Varma, and C.L. Kaul J. Chromatogr. B 806 2004 277 282
17. L.M. Mrsch, C.F. Bittencourt, M.J. eSouze, and J. Milano J. Pharm. Biomed. Anal. 30 2002 643 649
18. K.R. Tambwekar, R.B. Kakariya, and S. Garg J. Pharm. Biomed. Anal. 32 2003 441 450
19. Guidance for Industry, Oral extended (controlled) release dosage forms: in vivo bioequivalence and in vitro dissolution testing, US Department of Health and Human Services US FDA, Center for Drug Evaluation and Research, Rockville, MD, USA, 1993.
20. R.K. Verma, and S. Garg J. Pharm. Biomed. Anal. 35 2004 449 458